Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging drugs for ocular allergy.

Andrea Leonardi1

  • 1Department of Neuroscience, University of Padua, Via Giustiniani 2, 35128 Padova, Italy. andrea.leonardi@unipd.it

Expert Opinion on Emerging Drugs
|August 9, 2005
PubMed
Summary

Ocular allergy, or allergic conjunctivitis, involves eye inflammation. Current treatments like antihistamines are insufficient, necessitating research into novel topical anti-inflammatory agents for better ocular allergy management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Evolution of Treatment Outcomes with Once-Daily Ciclosporin A 0.1% Cationic Emulsion in Patients with Dry Eye Disease and Severe Keratitis.

Ophthalmology and therapy·2026
Same author

Impact of migalastat therapy on corneal deposits in a female with Fabry disease: A case report.

Molecular genetics and metabolism reports·2026
Same author

Suboptimal Responses to Anti-VEGF in Retinal Neurovascular Diseases: Linking Aging and Alternative Angioinflammatory Pathways.

Investigative ophthalmology & visual science·2026
Same author

Ocular Microbiome in Dupilumab-Induced Ocular Surface Disease.

Allergy·2025
Same author

Drug-Induced Periocular and Ocular Surface Disorders: An EAACI Position Paper.

Allergy·2025
Same author

Recent Advances in Targeted Immunomodulatory Therapies for Chronic Ocular Surface Diseases.

Seminars in ophthalmology·2025

Area of Science:

  • Ophthalmology
  • Allergology
  • Immunology

Background:

  • Ocular allergy, commonly allergic conjunctivitis, affects the conjunctiva.
  • Disease severity ranges from mild itching to sight-threatening conditions like vernal and atopic keratoconjunctivitis.
  • Pathogenesis involves IgE-mediated mast cell degranulation and immune cell activation.

Purpose of the Study:

  • To review the background of ocular allergic diseases.
  • To discuss the medical need for effective therapies.
  • To explore current and potential new treatments for ocular allergy.

Main Methods:

  • Literature review of ocular allergy.
  • Analysis of current pharmacotherapy for allergic conjunctivitis.
  • Examination of ongoing clinical trials for new agents.

Main Results:

  • Current pharmacotherapy includes antihistamines, mast cell stabilizers, dual-acting agents, and corticosteroids.
  • Existing treatments do not fully resolve ocular allergy symptoms.
  • New topical antiallergic/anti-inflammatory agents are under active clinical investigation.

Conclusions:

  • There is a significant unmet need for improved ocular allergy treatments.
  • Ongoing research focuses on developing novel topical agents to address limitations of current therapies.
  • Further investigation into new treatments is crucial for managing allergic conjunctivitis effectively.

Related Experiment Videos